The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 8, 2013, Pages 977-987

  Eaton, J E ^a   Smyrk, T C ^b   Imam, M ^a   Pardi, D S ^a   Loftus, E V ^a   Owens, V L ^b   Talwalkar, J A ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL FEATURE; COLON DISEASE; COLON RESECTION; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DYSPLASIA; FEMALE; FOLLOW UP; HIGH GRADE DYSPLASIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDEFINITE DYSPLASIA; LIVER TRANSPLANTATION; LOW GRADE DYSPLASIA; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; ULCERATIVE COLITIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLANGITIS, SCLEROSING; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MESALAMINE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; YOUNG ADULT;

EID: 84884910390     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12469     Document Type: Article

References (41)

1. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL,. Current concepts. Primary sclerosing cholangitis. N Engl J Med 1984; 310: 899-903.
2. Ludwig J, LaRusso NF, Wiesner RH,. The syndrome of primary sclerosing cholangitis. Prog Liver Dis 1990; 9: 555-66.
3. Bambha K, Kim WR, Talwalkar J, et al,. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125: 1364-9.
4. Marchesa P, Lashner BA, Lavery IC, et al,. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997; 92: 1285-8.
5. Chapman R, Fevery J, Kalloo A, et al,. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-78.
6. Farraye FA, Odze RD, Eaden J, Itzkowitz SH,. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 746-74.
7. Bernstein CN, Shanahan F, Weinstein WM,. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994; 343: 71-4.
8. Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH,. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107: 934-44.
9. Ullman TA, Loftus EV Jr, Kakar S, Burgart LJ, Sandborn WJ, Tremaine WJ,. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 2002; 97: 922-7.
10. Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S,. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003; 125: 1311-9.
11. Rutter MD, Saunders BP, Wilkinson KH, et al,. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130: 1030-8.
12. Jess T, Loftus EV Jr, Velayos FS, et al,. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis 2006; 12: 669-76.
13. Pekow JR, Hetzel JT, Rothe JA, et al,. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis 2010; 16: 1352-6.
14. Lim CH, Dixon MF, Vail A, Forman D, Lynch DA, Axon AT,. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003; 52: 1127-32.
15. van Schaik FD, ten Kate FJ, Offerhaus GJ, et al,. Misclassification of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia. Inflamm Bowel Dis 2011; 17: 1108-16.
16. Navaneethan U, Choudhary M, Venkatesh PG, et al,. The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2012; 35: 1054-63.
17. Marelli L, Xirouchakis E, Kalambokis G, Cholongitas E, Hamilton MI, Burroughs AK,. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 2011; 60: 1224-8.
18. Navaneethan U, Venkatesh PG, Mukewar S, et al,. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012; 10: 540-6.
19. Jorgensen KK, Lindstrom L, Cvancarova M, et al,. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scand J Gastroenterol 2012; 8-9: 1021-9.
20. Loftus EV Jr, Aguilar HI, Sandborn WJ, et al,. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998; 27: 685-90.
21. Torres J, Pineton de Chambrun G, Itzkowitz S, Sachar DB, Colombel JF,. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 497-508.
22. Eaton JE, Silveira MG, Pardi DS, et al,. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011; 106: 1638-45.
23. Tung BY, Emond MJ, Haggitt RC, et al,. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95.
24. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD,. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-93.
25. Wolf JM, Rybicki LA, Lashner BA,. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005; 22: 783-8.
26. Lindberg BU, Broome U, Persson B,. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001; 44: 77-85.
27. Velayos FS, Terdiman JP, Walsh JM,. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-53.
28. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
29. Riddell RH, Goldman H, Ransohoff DF, et al,. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983; 14: 931-68.
30. Ludwig J, LaRusso N, Wiesner RH,. Primary sclerosing cholangitis. In:, Peters RL, Craig JR, eds. Contemporary Issues in Surgical Pathology: Liver Pathology, Vol. 1. New York: Churchill Livingstone, 1986; 193-213.
31. Odze RD,. Adenomas and adenoma-like DALMs in chronic ulcerative colitis: a clinical, pathological, and molecular review. Am J Gastroenterol 1999; 94: 1746-50.
32. Rutter M, Saunders B, Wilkinson K, et al,. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-9.
33. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA,. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999; 94: 1643-9.
34. Kay RM,. Effects of diet on the fecal excretion and bacterial modification of acidic and neutral steroids, and implications for colon carcinogenesis. Cancer Res 1981; 41 (2): 3774-7.
35. Nagengast FM, Grubben MJ, van Munster IP,. Role of bile acids in colorectal carcinogenesis. Eur J Cancer 1995; 31A: 1067-70.
36. Bernstein H, Bernstein C, Payne CM, Dvorak K,. Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J Gastroenterol 2009; 15: 3329-40.
37. Ullman T, Croog V, Harpaz N, et al,. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol 2008; 6: 1225-30.
38. Eaden J, Abrams K, McKay H, Denley H, Mayberry J,. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol 2001; 194: 152-7.
39. Melville DM, Jass JR, Morson BC, et al,. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol 1989; 20: 1008-14.
40. Dixon MF, Brown LJ, Gilmour HM, et al,. Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology 1988; 13: 385-97.
41. Venkatesh PGK, Jegadeesan R, Gutierrez NG, et al,. Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohns Colitis 2013; doi: 10.1016/j.4crohns.2013.02.002 [Epub ahead of print].